This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sucampo And Takeda Announce Update On Liquid Formulation Program For AMITIZA(R) (lubiprostone)

BETHESDA, Md., March 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharma Americas, LLC, a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), and its development and commercialization partner's subsidiary Takeda Pharmaceuticals U.S.A., Inc. (Takeda) today announced that the New Drug Application (NDA) for the liquid formulation of AMITIZA ® (lubiprostone) will not be filed in the second half of 2014. In preliminary pre-NDA meeting comments, the FDA informed Sucampo that it would require additional data to characterize pharmacokinetics (PK) of the new formulation.
Takeda Pharmaceuticals U.S.A., Inc. logo

Sucampo and Takeda announced topline results from a pharmacodynamic, PK and tolerability study of a liquid formulation of AMITIZA in adults with chronic idiopathic constipation (CIC). The study showed directional improvement in spontaneous bowel movement (SBM) frequency in favor of liquid AMITIZA compared to placebo, but did not reach statistical significance. The safety profile observed in this study was consistent with previous clinical studies of AMITIZA. As a result of this outcome in conjunction with the FDA feedback, Sucampo and Takeda are now assessing next steps, which may include formulation modification. The companies are also evaluating potential impact to the timing of initiation of the second pivotal trial in the global, multicenter Phase 3 program for pediatric functional constipation in children aged 6 months to less than 6 years, as the liquid formulation would be required for this study.

"As we have previously disclosed, our goals in developing a liquid formulation of AMITIZA are to help meet the needs of patients who will not take AMITIZA in its capsule form, as well as to support our pediatric clinical program," said Peter Greenleaf, Sucampo's Chief Executive Officer. "The FDA feedback and study results provide useful direction as we seek to develop an alternative formulation of AMITIZA for a wider range of patients who may need it."

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs